The ESPAC-1, ESPAC-1 plus, and early ESPAC-3(v1) results (458 randomized patients; 364 deaths) were used to estimate the effectiveness of adjuvant 5FU/FA vs resection alone for pancreatic cancer using meta-analysis. The pooled hazard ratio of 0.70 (95% CI = 0.55-0.88) P = 0.003, and the median survival of 23.2 (95% CI = 20.1-26.5) months with 5FU/FA vs 16.8 (95% CI = 14.3-19.2) months with resection alone supports the use of adjuvant 5FU/FA in pancreatic cancer.
|Number of pages||5|
|Journal||British Journal of Cancer|
|Publication status||Published - 1 Jan 2009|
- pancreatic cancer
- randomized trial